α 7 nicotinic receptor agonists as cognitive treatments: Is less (or less often) more?

Biological Psychiatry

Volumn 69, Issue 1, 2011, Pages 5-6

  Buchanan, Robert W ^a   Schwarcz, Robert ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE) ABABESINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ACETYLCHOLINE; ALPHA7 NICOTINIC RECEPTOR AGONIST; AZD 0328; CHOLINERGIC RECEPTOR STIMULATING AGENT; CYCLOSERINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NICOTINIC AGENT; UNCLASSIFIED DRUG;

CLINICAL EFFECTIVENESS; COGNITION; COGNITIVE DEFECT; DOSE RESPONSE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HUMAN; LOW DRUG DOSE; MEMORY DISORDER; NONHUMAN; NOTE; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; RECEPTOR SENSITIVITY; RHESUS MONKEY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; COGNITION DISORDERS; HUMANS; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SCHIZOPHRENIA;

EID: 78649998196     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.11.004     Document Type: Note

References (10)

1. S. Sydserff, E.J. Sutton, D. Song, M.C. Quirk, C. Maciag, and C. Li Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes Biochem Pharmacol 78 2009 880 888
2. S.A. Castner, G.N. Smagin, T.M. Piser, Y. Wang, J.S. Smith, and E.P. Christian Immediate and sustained improvements in working memory after selective stimulation of α7 nicotinic acetylcholine receptors Biol Psychiatry 69 2011 12 18
3. D.V. Widzowski, D. Maier, J. McLaughlin, K. Neilson, M.J. Bock, and Y. Wang AZD0328 and AZ11943872: α7 nicotinic agonists that reverse fimbria-fornix-transection-induced working memory deficits following acute or chronic administration Soc Neurosci Abstr 906 2007 21
4. R.C. Hogg, and D. Bertrand Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors Biochem Pharmacol 73 2007 459 468 (Pubitemid 46043572)
5. J.J. Buccafusco, S.R. Letchworth, M. Bencherif, and P.M. Lippiello Long-lasting cognitive improvement with nicotinic receptor agonists: Mechanisms of pharmacokinetic-pharmacodynamic discordance Trends Pharmacol Sci 26 2005 352 360
6. J.R. Tregellas, J. Tanabe, D.C. Rojas, S. Shatti, A. Olincy, and L. Johnson Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia Biol Psychiatry 69 2011 7 11
7. A.G. Garrity, G.D. Pearlson, K. McKiernan, D. Lloyd, K.A. Kiehl, and V.D. Calhoun Aberrant "default mode" functional connectivity in schizophrenia Am J Psychiatry 164 2007 450 457
8. R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, and L. Johnson Initial phase 2 trial of a nicotinic agonist in schizophrenia Am J Psychiatry 165 2008 1040 1047
9. S.A. Castner, G.V. Williams, and P.S. Goldman-Rakic Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation Science 287 2000 2020 2022
10. D.C. Goff, C. Cather, J.D. Gottlieb, A.E. Evins, J. Walsh, and L. Raeke Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study Schizophr Res 106 2008 320 327